RxDoctor Payments Data

William Mania, MD

Internal Medicine · Richardson, TXNPI 1770599326

Payments from drug & device makers

$3,005in general payments, 2019–2025

Across 75 payments — averaging $40.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$505
  • AbbVie$443
  • Otsuka America Pharmaceutical, Inc.$433
  • Novo Nordisk$285
  • Eisai Inc.$155
  • Johnson & Johnson$154
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$371%
  • Food & beverage$2,96899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,005 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$103,156
Medicare patients
260
Services billed
34,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$31,271
JanuviaSitagliptin Phosphate18$20,387
EliquisApixaban12$20,334
PremarinEstrogens, Conjugated17$6,363
FingolimodFingolimod Hcl12$2,529
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$2,283
Divalproex Sodium ErDivalproex Sodium15$2,064
Tamsulosin Hcl122$2,049
Levothyroxine Sodium173$1,510
Simvastatin195$1,501
Gabapentin133$1,446
Atorvastatin Calcium131$1,334
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,298
SynthroidLevothyroxine Sodium18$1,271
Lisinopril245$1,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$43$31,27125 claims
PfizerEliquis, Premarin$505$26,69829 claims
MerckJanuvia$28$20,38718 claims
AbbVieSynthroid$443$1,27118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →